{"transactions":[{"id":2056296,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common share","published_at":"2023-01-11T20:42:13.000Z","date":"2023-01-10","kind":"sale","acquired":false,"shares":12895,"price":2.6346,"value":33973.167,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc. (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P. the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":150275,"source":{"system":"sec-edgar","filing":"0001213900-23-002248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000121390023002248/ownership.xml","form_type":"4"}},{"id":2056295,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common share","published_at":"2023-01-11T20:42:13.000Z","date":"2023-01-10","kind":"sale","acquired":false,"shares":139450,"price":2.6346,"value":367394.97,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc. (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P. the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1625133,"source":{"system":"sec-edgar","filing":"0001213900-23-002248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000121390023002248/ownership.xml","form_type":"4"}},{"id":2056294,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common share","published_at":"2023-01-11T20:42:13.000Z","date":"2023-01-09","kind":"sale","acquired":false,"shares":12284,"price":2.6621,"value":32701.2364,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc. (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P. the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":163170,"source":{"system":"sec-edgar","filing":"0001213900-23-002248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000121390023002248/ownership.xml","form_type":"4"}},{"id":2056293,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common share","published_at":"2023-01-11T20:42:13.000Z","date":"2023-01-09","kind":"sale","acquired":false,"shares":132845,"price":2.6621,"value":353646.6745,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc. (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P. the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1764583,"source":{"system":"sec-edgar","filing":"0001213900-23-002248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000121390023002248/ownership.xml","form_type":"4"}},{"id":2739372,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2021-04-26T20:55:41.000Z","date":"2021-04-22","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in equal proportions over 12 months beginning on the Grant Date."}],"balance_after":20000,"derivative":{"exercise_price":5.45,"expiration_date":"2031-04-22","underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001654954-21-004628","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495421004628/section16.xml","form_type":"4"}},{"id":2994236,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-11-03T18:18:59.000Z","date":"2020-11-02","kind":"other","acquired":false,"shares":5952,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":4,"exercise_date":"2020-07-08","expiration_date":"2020-11-08","underlying":"Common Shares","underlying_shares":5952},"source":{"system":"sec-edgar","filing":"0001654954-20-011786","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420011786/section16.xml","form_type":"4"}},{"id":2994235,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-11-03T18:18:59.000Z","date":"2020-11-02","kind":"other","acquired":false,"shares":64362,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":4,"exercise_date":"2020-07-08","expiration_date":"2020-11-08","underlying":"Common Shares","underlying_shares":64362},"source":{"system":"sec-edgar","filing":"0001654954-20-011786","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420011786/section16.xml","form_type":"4"}},{"id":2994234,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2020-11-03T18:18:59.000Z","date":"2020-11-02","kind":"other","acquired":true,"shares":5952,"price":4,"value":23808.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":175454,"source":{"system":"sec-edgar","filing":"0001654954-20-011786","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420011786/section16.xml","form_type":"4"}},{"id":2994233,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2020-11-03T18:18:59.000Z","date":"2020-11-02","kind":"other","acquired":true,"shares":64362,"price":4,"value":257448.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1897428,"source":{"system":"sec-edgar","filing":"0001654954-20-011786","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420011786/section16.xml","form_type":"4"}},{"id":3006844,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock option (right to buy)","published_at":"2020-10-14T19:51:39.000Z","date":"2020-10-13","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in equal proportions over 36 months beginning on the Grant Date."}],"balance_after":20000,"derivative":{"exercise_price":7.44,"expiration_date":"2030-10-13","underlying":"Common shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001654954-20-011142","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420011142/section16.xml","form_type":"4"}},{"id":3269971,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Share Option (Right to Buy)","published_at":"2020-02-14T23:19:50.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":11389,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33% vested on 2/12/2020, with a prorata amount of the balance vesting monthly thereafter over the next 36 months until fully vested."}],"balance_after":11389,"derivative":{"exercise_price":3.16,"expiration_date":"2030-02-12","underlying":"Common Shares","underlying_shares":11389},"source":{"system":"sec-edgar","filing":"0001654954-20-001653","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420001653/section16.xml","form_type":"4"}},{"id":3312361,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-13T15:11:48.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":5952,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Amended to reflect acquisition from the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to\npurchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc.\nLumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van\nder Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van\nder Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":5952,"derivative":{"exercise_price":4,"exercise_date":"2020-07-08","expiration_date":"2020-11-08","underlying":"Common Shares","underlying_shares":5952},"source":{"system":"sec-edgar","filing":"0001654954-20-000350","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000350/section16.xml","form_type":"4/A","original_submission_date":"2020-01-10"}},{"id":3312360,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-13T15:11:48.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":64362,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Amended to reflect acquisition from the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to\npurchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc.\nLumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van\nder Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van\nder Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":64362,"derivative":{"exercise_price":4,"exercise_date":"2020-07-08","expiration_date":"2020-11-08","underlying":"Common Shares","underlying_shares":64362},"source":{"system":"sec-edgar","filing":"0001654954-20-000350","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000350/section16.xml","form_type":"4/A","original_submission_date":"2020-01-10"}},{"id":3312359,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-13T15:11:48.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":8928,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Amended to reflect acquisition from the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to\npurchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc.\nLumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van\nder Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van\nder Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":8928,"derivative":{"exercise_price":4.8,"exercise_date":"2020-07-08","expiration_date":"2023-07-08","underlying":"Common Shares","underlying_shares":8928},"source":{"system":"sec-edgar","filing":"0001654954-20-000350","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000350/section16.xml","form_type":"4/A","original_submission_date":"2020-01-10"}},{"id":3312358,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-13T15:11:48.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":96542,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Amended to reflect acquisition from the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to\npurchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc.\nLumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van\nder Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van\nder Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":96542,"derivative":{"exercise_price":4.8,"exercise_date":"2020-07-08","expiration_date":"2023-07-08","underlying":"Common Shares","underlying_shares":96542},"source":{"system":"sec-edgar","filing":"0001654954-20-000350","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000350/section16.xml","form_type":"4/A","original_submission_date":"2020-01-10"}},{"id":3312357,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2020-01-13T15:11:48.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":11903,"price":3.2,"value":38089.6,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Amended to reflect acquisition from the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to\npurchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc.\nLumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van\nder Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van\nder Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":169502,"source":{"system":"sec-edgar","filing":"0001654954-20-000350","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000350/section16.xml","form_type":"4/A","original_submission_date":"2020-01-10"}},{"id":3312356,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2020-01-13T15:11:48.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":128722,"price":3.2,"value":411910.4,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Amended to reflect acquisition from the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to\npurchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc.\nLumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van\nder Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van\nder Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1833066,"source":{"system":"sec-edgar","filing":"0001654954-20-000350","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000350/section16.xml","form_type":"4/A","original_submission_date":"2020-01-10"}},{"id":3313106,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-10T19:13:35.000Z","date":"2020-01-08","kind":"purchase","acquired":true,"shares":5952,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share.  Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":5952,"derivative":{"exercise_price":4,"exercise_date":"2020-07-08","expiration_date":"2020-11-08","underlying":"Common Shares","underlying_shares":5952},"source":{"system":"sec-edgar","filing":"0001654954-20-000270","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000270/section16.xml","form_type":"4"}},{"id":3313105,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-10T19:13:35.000Z","date":"2020-01-08","kind":"purchase","acquired":true,"shares":64362,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share.  Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":64362,"derivative":{"exercise_price":4,"exercise_date":"2020-07-08","expiration_date":"2020-11-08","underlying":"Common Shares","underlying_shares":64362},"source":{"system":"sec-edgar","filing":"0001654954-20-000270","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000270/section16.xml","form_type":"4"}},{"id":3313104,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-10T19:13:35.000Z","date":"2020-01-08","kind":"purchase","acquired":true,"shares":8928,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share.  Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":8928,"derivative":{"exercise_price":4.8,"exercise_date":"2020-07-08","expiration_date":"2023-07-08","underlying":"Common Shares","underlying_shares":8928},"source":{"system":"sec-edgar","filing":"0001654954-20-000270","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000270/section16.xml","form_type":"4"}},{"id":3313103,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Share Warrants (Right to Buy)","published_at":"2020-01-10T19:13:35.000Z","date":"2020-01-08","kind":"purchase","acquired":true,"shares":96542,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share.  Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":96542,"derivative":{"exercise_price":4.8,"exercise_date":"2020-07-08","expiration_date":"2023-07-08","underlying":"Common Shares","underlying_shares":96542},"source":{"system":"sec-edgar","filing":"0001654954-20-000270","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000270/section16.xml","form_type":"4"}},{"id":3313102,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2020-01-10T19:13:35.000Z","date":"2020-01-08","kind":"purchase","acquired":true,"shares":11903,"price":3.2,"value":38089.6,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share.  Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":169502,"source":{"system":"sec-edgar","filing":"0001654954-20-000270","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000270/section16.xml","form_type":"4"}},{"id":3313101,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"ten_percent_owner":true}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2020-01-10T19:13:35.000Z","date":"2020-01-08","kind":"purchase","acquired":true,"shares":128722,"price":3.2,"value":411910.4,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share.  Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1833066,"source":{"system":"sec-edgar","filing":"0001654954-20-000270","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495420000270/section16.xml","form_type":"4"}},{"id":3452999,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-07-30T23:22:43.000Z","date":"2019-07-26","kind":"grant","acquired":true,"shares":8600,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents additional common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) (the \"Issuer\") issued pursuant to the post-closing adjustment contemplated by that certain Share Exchange Agreement, dated as of March 7, 2019, by and among the Issuer, Edesa Biotech, Inc. (\"Edesa\"), and the shareholders of Edesa.  The closing of the share exchange transaction contemplated by the Share Exchange Agreement occurred on June 7, 2019, at which time the Issuer acquired all the outstanding capital shares of Edesa from the Edesa shareholders."},{"field":"shares","element":"transactionShares","label":"F2","text":"All share numbers reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":157599,"source":{"system":"sec-edgar","filing":"0001104659-19-042699","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000110465919042699/a4.xml","form_type":"4"}},{"id":3452998,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-07-30T23:22:43.000Z","date":"2019-07-26","kind":"grant","acquired":true,"shares":93006,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents additional common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) (the \"Issuer\") issued pursuant to the post-closing adjustment contemplated by that certain Share Exchange Agreement, dated as of March 7, 2019, by and among the Issuer, Edesa Biotech, Inc. (\"Edesa\"), and the shareholders of Edesa.  The closing of the share exchange transaction contemplated by the Share Exchange Agreement occurred on June 7, 2019, at which time the Issuer acquired all the outstanding capital shares of Edesa from the Edesa shareholders."},{"field":"shares","element":"transactionShares","label":"F2","text":"All share numbers reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. (\"LCII LP\"), (ii) Lumira Capital II (International), L.P. (\"LCII INT LP\"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1704344,"source":{"system":"sec-edgar","filing":"0001104659-19-042699","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000110465919042699/a4.xml","form_type":"4"}},{"id":3493755,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-11T21:52:35.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":148999,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II (International), L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.)(the \"Issuer\") issued in the share exchange transaction that was completed on June 7, 2019, pursuant to that certain Share Exchange Agreement, dated March 7, 2019, by and among the Issuer, Edesa Biotech Inc. and the shareholders of Edesa Biotech Inc."},{"field":"shares","element":"transactionShares","label":"F3","text":"All share numbers reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. [\"LCII LP\"], (ii) Lumira Capital II (International), L.P. [\"LCII INT LP\"], (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co. and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc. Lumira GP Holdings Co. and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":148999,"source":{"system":"sec-edgar","filing":"0001144204-19-030609","document":"tv523428_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000114420419030609/tv523428_4.xml","form_type":"4"}},{"id":3493754,"issuer":{"id":7223,"kind":"organization","name":"Edesa Biotech, Inc.","symbol":"EDSA"},"owners":[{"id":120760,"kind":"person","name":"van der Velden Peter","position":1,"cik":"0001778046","reported_name":"van der Velden Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":2,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-11T21:52:35.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":1611338,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Lumira Capital II, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.)(the \"Issuer\") issued in the share exchange transaction that was completed on June 7, 2019, pursuant to that certain Share Exchange Agreement, dated March 7, 2019, by and among the Issuer, Edesa Biotech Inc. and the shareholders of Edesa Biotech Inc."},{"field":"shares","element":"transactionShares","label":"F3","text":"All share numbers reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is jointly filed by (i) Lumira Capital II, L.P. [\"LCII LP\"], (ii) Lumira Capital II (International), L.P. [\"LCII INT LP\"], (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co. and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc. Lumira GP Holdings Co. and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1611338,"source":{"system":"sec-edgar","filing":"0001144204-19-030609","document":"tv523428_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1540159/000114420419030609/tv523428_4.xml","form_type":"4"}}]}